Edwards Lifesciences Co. (NYSE:EW) CFO Scott B. Ullem Sells 5,625 Shares

Edwards Lifesciences Co. (NYSE:EW) CFO Scott B. Ullem sold 5,625 shares of the business’s stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $90.45, for a total transaction of $508,781.25. Following the transaction, the chief financial officer now directly owns 30,561 shares in the company, valued at approximately $2,764,242.45. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Edwards Lifesciences Price Performance

EW stock opened at $90.34 on Wednesday. The company has a market capitalization of $54.44 billion, a P/E ratio of 38.94, a PEG ratio of 3.26 and a beta of 1.10. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $96.12. The business has a 50 day simple moving average of $89.94 and a 200-day simple moving average of $81.28. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.02. The business had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.58 billion. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. As a group, equities analysts anticipate that Edwards Lifesciences Co. will post 2.77 EPS for the current year.

Institutional Investors Weigh In On Edwards Lifesciences

Several large investors have recently modified their holdings of EW. Norges Bank acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $648,540,000. Brown Advisory Inc. lifted its holdings in shares of Edwards Lifesciences by 20.1% during the fourth quarter. Brown Advisory Inc. now owns 18,181,420 shares of the medical research company’s stock worth $1,386,333,000 after purchasing an additional 3,048,274 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Edwards Lifesciences by 57.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company’s stock worth $622,695,000 after purchasing an additional 2,390,137 shares during the period. CIBC Private Wealth Group LLC lifted its holdings in shares of Edwards Lifesciences by 197.0% during the fourth quarter. CIBC Private Wealth Group LLC now owns 3,446,758 shares of the medical research company’s stock worth $262,815,000 after purchasing an additional 2,286,119 shares during the period. Finally, AustralianSuper Pty Ltd acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth $168,519,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently issued reports on EW. Stifel Nicolaus boosted their price objective on shares of Edwards Lifesciences from $83.00 to $85.00 and gave the company a “hold” rating in a report on Friday, April 26th. Citigroup boosted their price objective on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the company a “neutral” rating in a report on Wednesday, April 3rd. Oppenheimer boosted their price objective on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a report on Monday, March 18th. Royal Bank of Canada boosted their price target on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the stock an “outperform” rating in a research note on Monday, April 15th. Finally, Evercore ISI cut their price target on shares of Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating on the stock in a research note on Friday, April 26th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $93.88.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.